marketcap
Facebook
Twitter
Telegram
Report an ErrorAnnual report 2022
added 02-27-2023
Rubius Therapeutics Financial Ratios 2011-2024 | RUBY
Annual Financial Ratios Rubius Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-0.1 | -4.3 | -3.6 | -3.7 | -6.0 | -4.8 | -9.1 | - | - | - | - | - |
P/S |
- | - | - | - | - | - | - | - | - | - | - | - |
EPS |
-2.0 | -2.2 | -2.1 | -2.1 | -2.3 | -5.5 | -1.6 | - | - | - | - | - |
EV (Enterprise Value) |
4.81 M | 765 M | 655 M | 635 M | 313 M | 256 M | 119 M | - | - | - | - | - |
EBITDA per Share |
-1.91 | -2.12 | -1.99 | -2.12 | -2.3 | -0.926 | -1.26 | - | - | - | - | - |
EV/EBITDA |
-3.8 | -5.9 | -3.4 | -2.8 | -2.6 | -9.0 | - | - | - | - | - | |
PEG |
-0.18 | 2.33 | -0.44 | 0.04 | -0.15 | 0.48 | - | - | - | - | - | |
P/B |
0.8 | 4.8 | 4.3 | 2.2 | 1.4 | -4.8 | -5.9 | - | - | - | - | - |
P/CF |
-0.1 | -5.9 | -4.8 | -4.0 | -7.3 | -8.6 | -10.1 | - | - | - | - | - |
ROE % |
-1187.40 | -109.94 | -118.49 | -59.61 | -22.70 | 100.37 | 64.33 | - | - | - | - | - |
ROA % |
-778.79 | -61.80 | -60.38 | -41.40 | -18.62 | -40.72 | -137.89 | - | - | - | - | - |
ROCE % |
-1179.34 | -108.86 | -117.58 | -46.97 | -19.97 | -43.04 | -211.25 | - | - | - | - | - |
Current Ratio |
2.9 | 2.3 | 2.0 | 8.6 | 20.7 | 14.7 | 2.4 | - | - | - | - | - |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Rubius Therapeutics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
- | -0.7 | -0.49 | -0.58 | - | -0.55 | -0.56 | -0.51 | -0.5 | -0.51 | -0.47 | -0.6 | -0.56 | -0.59 | -0.5 | -0.42 | -0.35 | -0.42 | -2.43 | -1.72 | -2.07 | -1.48 | -1.25 | -0.68 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
- | -0.62 | -0.44 | -0.55 | - | -0.51 | -0.52 | -0.48 | -0.49 | -0.43 | -0.42 | -0.59 | -0.57 | -0.58 | -0.51 | -0.44 | -0.37 | -0.43 | -2.28 | -1.72 | -1.17 | -1.45 | -1.13 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-257.08 | -278.94 | -128.96 | -101.65 | -54.93 | -83.56 | -180.17 | -279.63 | -384.03 | -371.62 | -312.77 | -253.93 | -75.84 | -66.54 | -13.62 | 40.60 | -41.73 | 5.29 | 39.28 | 66.55 | 89.25 | 49.15 | 21.87 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-75.77 | -89.34 | -66.08 | -59.44 | -36.08 | -50.68 | -97.47 | -145.17 | -195.70 | -192.37 | -173.41 | -154.45 | -52.67 | -47.08 | -11.18 | 25.80 | -34.23 | -44.82 | -50.39 | -54.82 | -36.21 | -19.94 | -8.87 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-251.00 | -273.32 | -127.33 | -101.32 | -54.82 | -82.88 | -88.94 | -96.67 | -117.58 | -106.09 | -95.39 | -83.81 | -61.85 | -52.69 | -42.02 | -32.15 | -23.32 | 24.08 | 58.50 | 84.37 | 88.08 | 48.09 | 20.68 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
- | 1.3 | 1.7 | 2.0 | 2.3 | 2.6 | 3.0 | 3.3 | 2.0 | 2.0 | 2.0 | 2.0 | 3.3 | 3.3 | 3.3 | 3.3 | 5.6 | 5.6 | 5.6 | 5.6 | 9.3 | 9.3 | 9.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency